Mr. Cable counsels boards of directors and management teams on corporate governance, mergers and acquisitions, and disclosure and securities law matters.
Mr. Cable represents buyers, sellers and investment banks in his M&A practice. Representative M&A transactions include the sale of Onyx Pharmaceuticals to Amgen ($10.4 billion), the sale of Eloqua to Oracle ($1 billion), the sale of Idenix to Merck ($3.8 billion), the sale of Pharmacyclics to AbbVie ($21 billion), the sale of Xoom to PayPal ($1 billion), the private company sale of Stemcentrix to Abbvie ($5.8 billion), the sale of Opower to Oracle ($600 million), the abandoned acquisition of NXP by Qualcomm ($47 billion), the Reverse Morris Trust merger of a division of Citrix into LogMeIn ($2 billion), the cross border private company acquisitions of Euticals ($358 million – Italy) and Gadea ($174 million – Spain) by AMRI, the acquisition of Auspex by Teva Pharmaceuticals ($3.5 billion), the 2017 sale of Neustar to Golden Gate ($2.9 billion), the 2017 sale of Lionbridge to HIG ($400 million), the 2017 sale of AMRI to Carlyle and GTCR ($1.9 billion), the 2017 sale of PAREXEL to Pamplona ($5 billion), the private company acquisition and subsequent 2018 sale of Cord Blood Registry by AMAG Pharmaceuticals, the 2018 cross border sale of inviCRO to Konica Minolta (Japan) ($300 million), the majority sale of Foundation Medicine to Roche ($1 billion) and the subsequent (2018) negotiated tender for the public stub by Roche ($2.4 billion), the 2018 merger of equals transaction between Keryx and Akebia ($1 billion), the 2019 acquisition of Civitas by Centerbridge ($1.4 billion) and the 2019 sale of Spark to Roche ($4.8 billion).
Mr. Cable is also retained from time to time to represent "independent" or "special" committees of the Board of Directors, most recently representing the independent committee of the Board of Directors of Sprint in the pending 2018 Sprint/T-Mobile transaction ($26 billion). In the course of his career, Mr. Cable has negotiated and executed over 300 M&A transactions.
Mr. Cable serves regularly as counsel to issuers in IPOs, most recently representing Moderna and Rubius in their record setting IPOs in the biotechnology industry. Mr. Cable also represents underwriters in such transactions, including Morgan Stanley, JPM and Citi.
Mr. Cable represents tech and life sciences companies in complex minority strategic transactions including KIND in its 2018 partnership with Mars, Cornerstone onDemand in its 2018 $300 million convertible debt PIPE with Silver Lake and Microsoft, and PTC in its 2018 $1 billion common stock PIPE and strategic partnership with Rockwell.
Mr. Cable periodically represents public companies in connection with highly confidential “activist” matters, including the successful negotiation of "Cooperation" Agreements with Elliott Management on behalf of Cognizant and Citrix.
Mr. Cable also represents a number of life sciences and technology companies as outside general counsel, including AMAG, ANSYS, Cerevel, Citrix, Cogen, Corbus, Integral, Moderna, Novelion, Ohana, PAREXEL, PTC, Radius, Rubius, Shields Healthcare Solutions, Spark and Yumanity. Mr. Cable also represents the health care delivery start-up founded by Amazon, Berkshire Hathaway and J.P. Morgan and led by Atul Gawande.
Mr. Cable serves as a member of the President's Leadership Council at Dartmouth College, as chairman emeritus of the Buckingham Browne & Nichols School and as a member of the Board of the Arthur L. Irving Institute for Energy & Society at Dartmouth College. He also served for more than a decade as a member of the Board of Fellows of Harvard Medical School.
Mr. Cable leads the firm’s Pro Bono efforts on behalf of Camp Harbor View, a summer enrichment program for Boston’s youth founded by Jack Connors.
Mr. Cable is also a member of the Goodwin Pro Bono team servicing the Boston Red Sox Foundation where Mr. Cable advises on Board and governance matters.